Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Helixon Biotechnology (Suzhou) Co., Ltd

Clinicaltrial registered28 Oct 2026

Helixon Biotechnology (Suzhou) Co., Ltd

28 Oct 2026: Trial registered · Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
28 Oct 2026
Title
Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Conditions
Health Adults, Asthma
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Australia
Country
Australia
Reference
NCT07900568
Location
Australia
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Helixon Biotechnology (Suzhou) Co., Ltd

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Australia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.